Board of Directors

Yujiro S. Hata

Yujiro S. Hata was elected to our Board of Directors in August 2021. He has more than 20 years of experience building companies that have developed innovative therapies. Mr. Hata currently serves as the Founder and CEO of IDEAYA Biosciences, an oncology-focused precision medicine company, which he founded in 2015. From 2015 to 2018, Mr. Hata served as an Executive-in-Residence at 5AM Ventures. From 2014 to August 2015, he was Chief Operating Officer at Flexus Biosciences where he helped lead the company through its acquisition by Bristol-Myers Squibb in April 2015, and then he served as Chief Operating Officer at RAPT Therapeutics (formerly FLX Bio). Before then, Mr. Hata held roles of increasing responsibility, most recently as Vice President, Corporate Development and Strategy, at Onyx Pharmaceuticals. Previously Mr. Hata held business development roles at Enanta and at ImClone Systems, now a subsidiary of Eli Lilly and Company. Mr. Hata serves on the Boards of Directors of Xencor and Expansion Therapeutics and is a Board Member of the Moores Cancer Center at the University of California, San Diego. He obtained his M.B.A. from the University of Pennsylvania, his B.A. in Chemistry from Colorado College, and participated in undergraduate studies in Chemistry and Biology at Oxford University.